Open Life Sciences (Aug 2022)

In silico and in vivo analysis of TIPE1 expression in diffuse large B cell lymphoma

  • Shen Pei,
  • Shen Xianjuan,
  • Chen Guo,
  • Zhao Chunmei,
  • Cai Hua,
  • Xu Xinxin,
  • Duan Yinong,
  • Wang Xudong,
  • Ju Shaoqing

DOI
https://doi.org/10.1515/biol-2022-0099
Journal volume & issue
Vol. 17, no. 1
pp. 1030 – 1037

Abstract

Read online

TIPE1 is a gene in the TNFAIP8 family involved in immune regulation and tumorigenesis. Although previous studies demonstrated that TIPE1 might play different roles in different tumors, its expression and role in lymphoma are unclear. Here we observed TIPE1 expression in diffuse large B cell lymphoma (DLBCL). Two microarrays containing 96 tumor tissue specimens were obtained from the Affiliated Hospital of Nantong University biobank. All specimens came from patients with a clear pathological diagnosis of lymphoma, lymphadenitis, breast cancer, or bladder cancer, and we performed immunohistochemical experiments on these tissue specimens. GEPIA and TIMER platforms were used for bioinformatic analyses. We found higher TIPE1 expression in tumor tissues from patients with lymphoma compared with those with lymphadenitis, breast cancer, or bladder cancer. The GEPIA and TIMER analyses revealed that TIPE1 was upregulated in DLBCL tissues but not in invasive breast carcinoma, urothelial bladder carcinoma, or liver hepatocellular carcinoma tissues. TIPE1 expression was irrelevant for pathological stage, overall survival, or DLBCL immune infiltration levels. However, TIPE1 expression was correlated with MKI67 expression in DLBCL. Overall, TIPE1’s high expression levels in DLBCL may contribute to tumor growth in DLBCL.

Keywords